Explore the vast range of titles available.

Purpose: Cisplatin/5-fluorouracil (5-FU) is an accepted palliative chemotherapy treatment for head and neck squamous cell carcinoma, improving quality of life but not overall survival. Capecitabine in place of 5-FU removes the morbidity of an infusional regime with potential benefit in patient well-being. This study looks at outcomes for cisplatin plus capecitabine (PX) outside of a trial setting. Methods: Consecutive patients receiving this treatment in a single centre were retrospectively analysed. Cisplatin (mean dose 75 mg/m 2 ) was given on day 1 of a 3-week cycle and capecitabine (mean dose 808 mg/m 2 twice daily) on days 1-14, for up to 6 cycles. Results: Sixty-five patients (median age 58.6 years) received a median of 4 cycles of chemotherapy. The overall response rate was 30.7%, with a median overall survival of 7.3 months. Treatment was well tolerated with a 10.7% grade 3 and a 1.5% grade 4 neutropenia rate, with no other grade 4 toxicities. One patient died of neutropenic sepsis whilst on treatment. Twenty-seven percent of patients stopped treatment early due to chemotherapy-related side effects. Conclusion: PX is well tolerated outside the trial setting with outcomes similar to historical published literature. Ease of administration and benefit to patient convenience make it an attractive alternative to standard palliative treatment.

We feature a 0.35-µm SiGe BiCMOS technology (SiGe 5PAe) that is optimized for power amplifier (PA) applications. The key feature of this technology is a novel low-inductance ground to the package using through-silicon vias (TSVs) that results in a competitive solution for future multiband and multimode PA integration. The tungsten-filled, multifinger, bar-shaped TSV delivers more than a 75% reduction in inductance compared to a traditional wirebond. This enables higher frequency applications with a roughly 20% reduction in die area without compromising the technology reliability for use conditions in a low-cost plastic QFN (quad flat no leads) package. In this paper we demonstrate the commercial feasibility of the TSV, its RF performance, its reliability, and its usefulness in a demanding WiMAX® (Worldwide Interoperability for Microwave Access) PA application. [PUBLICATION ABSTRACT]

The results of surgery for meconium ileus obstruction (37 cases) at Queen Elizabeth Hospital for Children, London, during the years 1953 to 1970 are presented. The surgical survival was 30% in the years 1953 to 1961, and 70% in the years 1962 to December 1970, inclusive. The long-term survival was 57%. Complications, such as small bowel atresia, gangrene, and meconium peritonitis, were associated with a higher mortality. The adoption of the Bishop Koop operation in 1962 coincided with the increase in the survival rate. An association between meconium ileus and hypertrophic pyloric stenosis was noted.